MARKET

ISO

ISO

ISOPLEXIS CORP
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.27
-1.54
-19.72%
Closed 16:00 01/27 EST
OPEN
7.69
PREV CLOSE
7.81
HIGH
7.91
LOW
6.18
VOLUME
143.97K
TURNOVER
--
52 WEEK HIGH
16.95
52 WEEK LOW
4.770
MARKET CAP
244.25M
P/E (TTM)
-3.3925
1D
5D
1M
3M
1Y
5Y
IsoPlexis 3-day run comes to an end as shares fall 19%
A 3-day run for IsoPlexis (ISO -19.0%), which offers a single cell proteomics platform, is over as shares are down significantly today. From Friday's close through yesterday's close, shares rose
Seekingalpha · 5h ago
Where IsoPlexis Stands With Analysts
Over the past 3 months, 5 analysts have published their opinion on IsoPlexis (NASDAQ:ISO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the ...
Benzinga · 6h ago
IsoPlexis sees FY 2021 revenue as high as $17.2M, above consensus
IsoPlexis (NASDAQ:ISO) announces preliminary revenue for FY 2021. Total revenue for 2021 is expected to be in the range of $17M to $17.2M (consensus $16.71M), representing an increase of ~64%
Seekingalpha · 01/10 10:36
IsoPlexis Reports Preliminary Full Year 2021 Revenue, Releases Industry-First Superhuman Cell Library
Superhero cells are key to the efficacy, potency, and durability of therapies across the human health spectrumBRANFORD, Conn., Jan. 09, 2022 (GLOBE NEWSWIRE) -- IsoPlexis (NASDAQ: ISO), the Superhuman Cell Company, today announced its preliminary unaudited...
GlobeNewswire · 01/10 00:00
What Is The Ownership Structure Like For IsoPlexis Corporation (NASDAQ:ISO)?
The big shareholder groups in IsoPlexis Corporation ( NASDAQ:ISO ) have power over the company. Institutions often own...
Simply Wall St. · 01/08 13:56
ISO, CMMB and CTMX among technology movers
Gainers: Reliance Global Group (NASDAQ:RELI) +89%. Biofrontera  (NASDAQ:BFRI) +49%. IsoPlexis Corporation (NASDAQ:ISO) +37%. Chemomab Therapeutics  (NASDAQ:CMMB) +29%. iSpecimen  (NASDAQ:ISPC) +28%. Aldeyra Therapeutics (NASDAQ:ALDX) -51%. DBV Technologies...
Seekingalpha · 12/21/2021 20:44
JAGX, SEAC and EQOS among mid-day movers
Gainers: Reliance Global Group (NASDAQ:RELI) +82%. Biofrontera (NASDAQ:BFRI) +49%. Jaguar Health (NASDAQ:JAGX) +43%. IsoPlexis (NASDAQ:ISO) +31%. Aridis Pharmaceuticals (NASDAQ:ARDS) +28%. Petros Pharmaceuticals (NASDAQ:PTPI) +30%. Eqonex (NASDAQ:EQOS) +26...
Seekingalpha · 12/21/2021 17:26
Inotiv, Theravance Biopharma leads healthcare gainers; Radius Health, Ensysce Biosciences among major losers
Gainers: Inotiv (NASDAQ:NOTV) +13%, Theravance Biopharma (NASDAQ:TBPH) +11%, Biofrontera (NASDAQ:BFRA) +11%, Dare Bioscience (NASDAQ:DARE) +10%, Stereotaxis, Inc. (NYSE:STXS) +8%. Losers: Radius Health RDUS -43%, Ensysce Biosciences (NASDAQ:ENSC) -27%, Cor...
Seekingalpha · 12/08/2021 16:13
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ISO. Analyze the recent business situations of ISOPLEXIS CORP through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

25.00%Strong Buy
75.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ISO stock price target is 20.33 with a high estimate of 24.00 and a low estimate of 17.00.
High24.00
Average20.33
Low17.00
Current 6.27
EPS
Actual
Estimate
-8.53-6.40-4.26-2.13
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 1
Institutional Holdings: 2.00K
% Owned: 0.01%
Shares Outstanding: 38.95M
TypeInstitutionsShares
Increased
0
0
New
1
2.00K
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-1.05%
Healthcare Equipment & Supplies
-0.89%
Key Executives
Chairman/Director
John Conley
Chief Executive Officer/Co-Founder/Director
Sean Mackay
Chief Financial Officer/Primary Contact
John Strahley
Senior Vice President/General Counsel/Secretary
Richard Rew
Senior Vice President/Director of Sales
Verna Siu
Controller
Manny Resendes
Director
Gregory Ho
Director
Daniel Wagner
No Data
About ISO
IsoPlexis Corporation is a life sciences company. It is engaged in building solutions to develop curative medicines and personalized therapeutics. The Company's single-cell proteomics systems reveal biological activity in small subsets of cells, allowing researchers to connect directly to in-vivo biology and develop precise and personalized therapies. Its focuses on developing applications of its platform for cancer immunology and cell and gene therapy. The Company's platform is comprised of IsoLight and IsoSpark instruments, IsoCode and CodePlex chip consumables, and IsoSpeak software. Its IsoLight and IsoSpark instruments is designed to be automated benchtop proteomic hubs. Its IsoCode chips uses it technology proteomic barcoding to capture single cell protein information. Its CodePlex chips technology is used to test multiplexed bulk proteins. IsoSpeak software provides automated data analysis and accelerated insights. Its subsidiary includes IsoPlexis UK Limited.

Webull offers kinds of IsoPlexis Corp stock information, including NASDAQ:ISO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ISO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ISO stock methods without spending real money on the virtual paper trading platform.